THOMAS FRANK E purchased $22K of LRMR

THOMAS FRANK E purchased 8,000 shares of Larimar Therapeutics, Inc. (LRMR) at $2.72 on 2026-11-11.

Original reporting
SEC EDGAR · THOMAS FRANK E
Published Nov 12, 2026, 11:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Neutral
high confidence
Mentioned
$LRMR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRNeutralLow
01

Why it matters

The director's modest purchase adds a small positive data point but is unlikely to move the stock significantly.

02

Market read

A low‑value insider buy; limited trading relevance.

03

What to watch

Potential upcoming clinical data could be the real driver behind the purchase.

Relevance 4/10Novelty 4/10Timing: post-market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$LRMRNeutralHigh confidence
Context

Director Thomas Frank purchased 8,000 shares at $2.725 each, total $21.8K, raising his holding to 15,000 shares.

Expected impact

modest upward pressure as market prices in insider confidence

Evidence & confidence

Form 4 is primary source; purchase amount is low relative to market cap, so impact is limited.

Market effects

minor signal for biotech sector confidence

limited to US biotech investors

low

Counterpoint

Insider purchase may be routine portfolio rebalancing, not a strong bullish cue.

Key entities

  • Larimar Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Thomas Frank

    Director of Larimar Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.